Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag
Latest Information Update: 07 May 2025
At a glance
- Drugs Eltrombopag (Primary)
- Indications Diamond-Blackfan syndrome
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 03 Dec 2024 Status changed from active, no longer recruiting to completed.
- 13 Dec 2022 Results assessing the safety and efficacy of daily, fixed-dose eltrombopag starting at 150 mg daily or pediatric weight-based equivalent for 6 months in patients with DBA, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 05 Oct 2022 Planned End Date changed from 1 May 2025 to 30 Jun 2027.